Domestic dogs are considered the reservoir species.

Profile
Definition n Canine distemper virus (CDV) is a morbillivirus in the Paramyxoviridae family. o The causal viruses of rinderpest and measles are also included in this family. n CDV is an enveloped virus.
o CDV is relatively easy to inactivate and requires only the removal of the lipid outer membrane. o Any disinfectant with detergent activity effectively inactivates this virus. n CDV, an RNA virus, has a significant mutation rate that is much greater than that of DNA viruses. n Domestic dogs are considered the reservoir species. n CDV also affects multiple wildlife species (eg, raccoons, skunks, foxes, ferrets) and can infect and cause disease in large felids (eg, lions). n Antigenic drift and strain diversity have been increasingly associated with outbreaks in wild species, domestic dogs, and exotic animals in zoos and parks. o New strains can emerge, so monitoring is necessary to ensure current vaccines are fully protective against predominant circulating strains.
Systems n The infection is associated with all lymphatic tissue.
n Respiratory, GI, and urogenital epithelium; CNS; and optic nerves are also infected.
Incidence & Prevalence n The virus occurs globally, but it is a rare disease in typical pet populations. n Disease can be common in areas of low vaccine coverage. 
Consultant on Call
Pitfalls
n CDV should not be ruled out simply because there is no history of contact with other dogs.
-Wildlife (eg, raccoons, foxes) can be an important source of CDV.
n Although current vaccines appear to be protective against most circulating strains, vaccine breaks may occur.
n PCR can detect virus from the vaccine for a few weeks postvaccination.
-It is important to know if the dog has recently been vaccinated when testing samples for CDV.
-The testing laboratory can help discern whether a positive result is from natural infection or vaccine. 
MORE
Diagnosis
Use in puppies and kittens:
The safety and effectiveness of vetsulin ® in puppies and kittens has not been evaluated.
ADVERSE REACTIONS Dogs
In the field effectiveness and safety study, 66 dogs were treated with vetsulin ® . Sixty-two dogs were included in the assessment of safety. Hypoglycemia (defined as blood glucose < 50 mg/dL) with or without associated clinical signs occurred in 35.5% (22/62) of the dogs at various times during the study. Clinical signs of hypoglycemia were generally mild in nature (described as weakness, lethargy, stumbling, falling down, and/or depression). Disorientation and collapse were reported less frequently and occurred in 16.1% (10/62) of the dogs. Two dogs had a seizure and one dog died during the seizure. Although never confirmed, the presumptive diagnosis was hypoglycemia-induced seizures. In the rest of the dogs, hypoglycemia resolved with appropriate therapy and adjustments in insulin dosage. Seven owners recorded the following observations about the injection site on thehome monitoring forms: swollen, painful, sore, and a bleb under the skin.
The following clinical observations occurred in the field study following treatment with vetsulin ® and may be directly attributed to the drug or may be secondary to the diabetic state or other underlying conditions in the dogs: hematuria, vomiting, diarrhea, pancreatitis, non-specific hepatopathy/pancreatitis, development of cataracts, and urinary tract infections. In a 21-day field safety and effectiveness study, 40 dogs, already well controlled on vetsulin ® , were administered vetsulin ® using a VetPen™ insulin pen loaded with a pre-filled 2.7 mL vetsulin ® cartridge and 29 gauge/12 mm pen needles. All dogs enrolled in the study were evaluated for safety. Loss of diabetic control was reported in 10 dogs, 3 of which were withdrawn from the study. Four dogs' loss of control resolved after dose adjustment while still using the insulin pen. For the remaining 3 dogs, the loss of diabetic control was reported at the end of the study and outcome was not documented. Two dogs had injection site reactions: edema in one dog and two instances of crusting in another. Poor appetite and weight loss was reported in one dog. Cats In a field effectiveness and safety study, safety data was reported for 78 cats receiving vetsulin ® . Hypoglycemia (defined as blood glucose < 50 mg/dL) was reported in 61 cats (88 total incidences). Fifteen of the occurrences (involving 13 cats) were associated with clinical signs described as lethargy, diarrhea, decreased appetite/anorexia, vomiting, and hypothermia. One cat had seizures following accidental overdosing by the owner and again during the subsequent dose adjustment period. The cat responded to supportive therapy and had no further hypoglycemic episodes. In all cases of hypoglycemia, the clinical signs resolved following symptomatic treatment and/or dose adjustment. Polyneuropathy was reported in 4 cats. Two injection site reactions were reported: one as a mildly thickened subcutaneous tissue reaction and the second as a mild bruising.
The following clinical observations occurred in the field study following treatment with vetsulin ® and may be directly attributed to the drug or may be secondary to the diabetic state or other underlying conditions in the cats: vomiting, lethargy, diarrhea, decreased appetite/anorexia, pancreatitis, dermal events, respiratory disease, urinary tract disorder, renal disease, dehydration, weight loss, polydipsia, polyuria, behavioral change, and ocular discharge/conjunctivitis. In a smaller field effectiveness and safety study, 14 cats were treated with vetsulin ® . Hypoglycemia was reported in 6 cats (8 total occurrences).
Lethargy not associated with hypoglycemia was reported in 4 cats (6 total occurrences).
The following clinical observations occurred in the field study following treatment with vetsulin ® and may be directly attributed to the drug or may be secondary to the diabetic state or other underlying conditions in the cats: foul odor to stool, diarrhea, dull coat, rapid, shallow breathing, stiff gait in rear, gallop rhythm, and pruritus with alopecia. During the 1998-2007 period, the following adverse events in 50 cats treated with porcine insulin zinc suspension were reported to Intervet International and Intervet Inc: Death, seizures, lack of effectiveness/dysregulation, hypoglycemia, allergic or skin reaction, lethargy, vomiting/diarrhea, injection pain, hyperthermia, nystagmus, PU/PD, and abnormal behavior. In a 21-day field safety and effectiveness study, 36 cats, already well controlled on vetsulin ® , were administered vetsulin ® using a VetPen TM insulin pen loaded with a pre-filled 2.7 mL vetsulin ® cartridge and 29 gauge/12 mm pen needles. Loss of diabetic control was reported in three cats all of which resolved after dose adjustment while still using the insulin pen. Hypoglycemia was reported in one cat. 
Follow-Up
Patient Monitoring n Infected dogs with systemic signs (eg, vomiting, diarrhea) should undergo extensive daily monitoring. n Disinfection of the environment (eg, shelter, house, kennel) is recommended. o CDV is extremely susceptible to common disinfectants.
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